

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number  
**WO 2004/105754 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/405**,  
31/40, C07D 209/26, 207/34, A61P 3/06

(21) International Application Number:  
PCT/EP2004/050897

(22) International Filing Date: 24 May 2004 (24.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03101530.8 27 May 2003 (27.05.2003) EP

(71) Applicant (for all designated States except US): **NICOX**  
S.A. [FR/FR]; 2455 Route des Dolines, Espace Gaia II -  
Batiment I, F-06906 Sophia Antipolis (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BENEDINI**,  
Francesca [IT/IT]; Via Padova 286, I-20132 Milano (IT).  
**ONGINI**, Ennio [IT/IT]; Via Fratelli Cervi, Residenza  
Sorgente, I-20090 Segrate (IT). **DEL SOLDATO**, Piero  
[IT/IT]; Via E. Toti 22, I-20052 Monza (IT).

(74) Agent: **BARCIELLI**, Giovanna; Nicox Research Insti-  
tute Srl, Via L. Ariosto 21, I-20091 Bresso (IT).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NITROOXYDERIVATIVES OF FLUVASTATIN, PRAVASTATIN, CERIVASTATIN, ATORVASTATIN AND ROSU-  
VASTATIN AS CHOLESTEROL-REDUCING AGENTS WITH IMPROVED ANTI-INFLAMMATORY, ANTITHROMBOTIC  
AND ANTIPLATELET ACTIVITY

(57) Abstract: Nitrooxyderivatives of fluvastatin, cerivastatin, atorvastatin and rosuvastatin having improved pharmacological ac-  
tivity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular  
coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.

WO 2004/105754 A1

NITROOXYDERIVATIVES OF FLUVASTATIN, PRAVASTATIN, CERIVASTATIN, ATORVASTATIN AND ROSUVASTATIN AS CHOLESTEROL-REDUCING AGENTS WITH IMPROVED ANTI-INFLAMMATORY, ANTITHROMBOTIC AND ANTIPLATELET ACTIVITY

5       The present invention relates to new statin derivatives. More particularly, the present invention relates to statin nitroderivatives, pharmaceutical compositions containing them and their use as cholesterol-reducing drugs, as drugs having immunosuppressive  
10 properties, antioxidant, antithrombotic and anti-inflammatory activity, effects on endothelial function, and for treating and/or preventing acute coronary syndromes, stroke, neurodegenerative disorders, such as Alzheimer's and Parkinson's disease as well as autoimmune diseases,  
15 such as multiple sclerosis.

      With statins a class of compounds is intended, comprising as main components lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, atorvastatin, rosuvastatin and cerivastatin (rivastatin). They possess a  
20 side group that is structurally similar to HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A). Fluvastatin, atorvastatin, rosuvastatin and cerivastatin are entirely synthetic compounds containing a heptanoic acid side chain, the remainders being fungal metabolites.


25       It is known that the various statins are inhibitors of HMG-CoA reductase, an enzyme which catalyses an early, rate-limiting step in cholesterol biosynthesis, reduce triglyceride levels and are also indicated for raising HDL-C levels (P.O. Bonetti et al., European Heart Journal  
30 (2003) 24, 225-248).

      However, it is also known that statins exhibit adverse effects, such as for example hepatopathy, possible

carcinogenic potential, muscular side-effects and, above all, myopathy.

It was now object of the present invention to provide new derivatives of statins able not only to eliminate or at least reduce the side effects associated with these compounds, but also having an improved pharmacological activity. It has been so surprisingly found that statin nitroderivatives have a significantly improved overall profile as compared to native statins both in term of wider pharmacological activity and enhanced tolerability. In particular, it has been recognized that the statin nitroderivatives of the present invention exhibit a strong anti-inflammatory, antithrombotic and antiplatelet activity and can be furthermore employed for reducing cholesterol and triglycerides levels, for raising HDL-C levels and for treating or preventing acute coronary syndromes, stroke, peripheral vascular diseases such as peripheral ischemia and all disorders associated with endothelial dysfunctions such as vascular complications in diabetic patients and atherosclerosis. They should also be employed for treating neurodegenerative and autoimmune diseases, such as Alzheimer's and Parkinson's disease as well as multiple sclerosis.

Object of the present invention are, therefore, statin nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof



(I)


wherein R is the statin residue exemplified below and Y is a suitable linker group, X being as defined below.

According to the present invention, the statin residue R in formula (I) is selected from the group consisting of pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin.



5 In particular, in the general formula (I) R, X and Y have the following meanings:

X is -O-, -S-, -NH- or -NHR<sup>1</sup>-, R<sup>1</sup> being straight or branched alkyl with 1 to 10 carbon atoms, preferably CH<sub>3</sub>;


R is




10



15



or




5 Y is a bivalent radical having the following meaning:


a)

- straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene, preferably C<sub>1</sub>-C<sub>10</sub>,  
being optionally substituted with one or more of the  
10 substituents selected from the group consisting of:  
halogen atoms, hydroxy, -ONO<sub>2</sub> or T<sub>0</sub>, wherein T<sub>0</sub> is  
-OC(O) (C<sub>1</sub>-C<sub>10</sub> alkyl)-ONO<sub>2</sub> or -O(C<sub>1</sub>-C<sub>10</sub> alkyl)-ONO<sub>2</sub>;
- cycloalkylene with 5 to 7 carbon atoms into  
cycloalkylene ring, the ring being eventually  
15 substituted with side chains T, wherein T is straight  
or branched alkyl with from 1 to 10 carbon atoms,  
preferably CH<sub>3</sub>;

b)




c)



5 wherein  $n$  is an integer from 0 to 20, and  $n^1$  is an integer from 1 to 20;

d)




10 wherein:

$n^1$  is as defined above and  $n^2$  is an integer from 0 to 2;

$\text{X}_1 = -\text{OCO}-$  or  $-\text{COO}-$  and  $\text{R}^2$  is H or  $\text{CH}_3$ ;

e)




15 wherein:

$n^1$ ,  $n^2$ ,  $\text{R}^2$  and  $\text{X}_1$  are as defined above;

$\text{Y}^1$  is  $-\text{CH}_2-\text{CH}_2-$  or  $-\text{CH}=\text{CH}-(\text{CH}_2)_{n^2}-$ ;

f)





20 wherein:

$n^1$  and  $\text{R}^2$  are as defined above,  $\text{R}^3$  is H or  $\text{COCH}_3$ ;


with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the -ONO<sub>2</sub> group is bound to -(CH<sub>2</sub>)<sub>n</sub><sup>1</sup>;

g)



wherein X<sub>2</sub> is -O- or -S-, n<sup>3</sup> is an integer from 1 to 6, preferably from 1 to 4, R<sup>2</sup> is as defined above;

h)




wherein:

n<sup>4</sup> is an integer from 0 to 10;

15 n<sup>5</sup> is an integer from 1 to 10;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> are the same or different, and are H or straight or branched C<sub>1</sub>-C<sub>4</sub>-alkyl, preferably R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> are H;


wherein the -ONO<sub>2</sub> group is linked to



wherein n<sup>5</sup> is as defined above;

Y<sup>2</sup> is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur,

25 and is selected from



5

The term "C<sub>1</sub>-C<sub>20</sub> alkylene" as used herein refers to branched or straight chain C<sub>1</sub>-C<sub>20</sub> hydrocarbon, preferably having from 1 to 10 carbon atoms such as methylene, ethylene, propylene, isopropylene, n-butylene, pentylene, n-hexylene and the like.

The term "C<sub>1</sub>-C<sub>10</sub> alkyl" as used herein refers to branched or straight chain alkyl groups comprising one to ten carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the like.

The term "cycloalkylene" as used herein refers to ring having from 5 to 7 carbon atoms including, but not limited to, cyclopentylene, cyclohexylene optionally substituted with side chains such as straight or branched (C<sub>1</sub>-C<sub>10</sub>)-alkyl, preferably CH<sub>3</sub>.

20



The term "heterocyclic" as used herein refers to saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulphur, such as for example pyridine, pyrazine, pyrimidine, pyrrolidine, morpholine, imidazole and the like.

Another aspect of the present invention provides the use of the compounds of formula (I) in combination with at least a compound used to treat cardiovascular disease selected from the group consisting of: ACE inhibitors, angiotensin II receptor antagonists, beta-adrenergic blockers, calcium channel blockers, antithrombotics such as aspirin, nitrosated ACE inhibitors, nitrosated angiotensin II receptor antagonists, nitrosated beta-adrenergic blockers and nitrosated aspirin.

Suitable ACE inhibitors, angiotensin II receptor antagonists, beta-adrenergic blockers, calcium channel blockers, antithrombotics are described in the literature such as The Merck Index (13<sup>th</sup> edition).

Suitable nitrosated compounds are disclosed in WO 98/21193 and WO 97/16405.

The administration of the compounds above reported can be carried out simultaneously or successively.

The present invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the compounds and/or compositions of the present invention and one or more of the compounds used to treat cardiovascular diseases reported above.

As stated above, the invention includes also the pharmaceutically acceptable salts of the compounds of formula (I) and stereoisomers thereof.

The compounds according to the present invention, when they contain in the molecule one salifiable nitrogen atom,

can be transformed into the corresponding salts by reaction in an organic solvent such as acetonitrile, tetrahydrofuran with the corresponding organic or inorganic acids.

Examples of organic acids are: oxalic, tartaric, maleic, succinic, citric acids. Examples of inorganic acids are: nitric, hydrochloric, sulphuric, phosphoric acids. Salts with nitric acid are preferred.

The compounds of the invention which have one or more asymmetric carbon atoms can exist as optically pure enantiomers, pure diastereomers, enantiomers mixtures, diastereomers mixtures, enantiomer racemic mixtures, racemates or racemate mixtures. Within the object of the invention are also all the possible isomers, stereoisomers and their mixtures of the compounds of formula (I).

Preferred compounds are those of formula (I) wherein:

X is -O- or -S-;


R is a statin residue as defined above;

Y is a bivalent radical having the following meaning:


a)

- straight or branched C<sub>1</sub>-C<sub>10</sub> alkylene, being optionally substituted with T<sub>0</sub>, wherein T<sub>0</sub> is as above defined;

b)




c)



25

wherein n is an integer from 0 to 5, and n<sup>1</sup> is an integer from 1 to 5;

d)




wherein:

$n^1$  is as defined above and  $n^2$  is an integer from 0 to 2;

5  $X_1 = -\text{OCO}-$  or  $-\text{COO}-$  and  $R^2$  is H or  $\text{CH}_3$ ;

e)




wherein:

$n^1$ ,  $n^2$ ,  $R^2$  and  $X_1$  are as defined above;

10  $Y^1$  is  $-\text{CH}=\text{CH}-$ ;

f)




wherein:

$n^1$  is as defined above,  $R^2$  is H or  $\text{CH}_3$ ,  $R^3$  is H or  $\text{COCH}_3$ ;

15 with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the  $-\text{ONO}_2$  group is bound to  $-(\text{CH}_2)_{n^1}$ ;


g)




20

wherein  $X_2$  is  $-\text{O}-$  or  $-\text{S}-$ ,  $n^3$  is an integer from 1 to 4, preferably 1,  $R^2$  is a hydrogen atom or  $\text{CH}_3$ ;

h)




wherein:

 $n^4$  is an integer from 0 to 3;5  $n^5$  is an integer from 1 to 3; $\text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7$  are the same and are H;and wherein the  $\text{-ONO}_2$  group is linked to

;

$\text{Y}^2$  is a 6 member saturated, unsaturated or aromatic  
 10 heterocyclic ring, containing one or more atoms of  
 nitrogen and selected for example from



15        The following are preferred compounds according to the  
 present invention:

fluvastatin 4-(nitrooxy)butyl ester,

fluvastatin 4-(nitrooxymethyl)benzyl ester,

fluvastatin 3-(nitrooxymethyl)benzyl ester,


20 fluvastatin 2-(nitrooxymethyl)benzyl ester,

fluvastatin 4-(nitrooxymethyl)phenyl ester,


fluvastatin 3-(nitrooxymethyl)phenyl ester,

fluvastatin 2-(nitrooxymethyl)phenyl ester,


fluvastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester,  
corresponding to formula:




fluvastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-  
5 propenoyloxy]phenol ester, corresponding to formula:




pravastatin 4-(nitrooxy)butyl ester,  
pravastatin 4-(nitrooxymethyl)benzyl ester,  
pravastatin 3-(nitrooxymethyl)benzyl ester,  
10 pravastatin 2-(nitrooxymethyl)benzyl ester,  
pravastatin 4-(nitrooxymethyl)phenyl ester,  
pravastatin 3-(nitrooxymethyl)phenyl ester,  
pravastatin 2-(nitrooxymethyl)phenyl ester,  
pravastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester,  
15 corresponding to formula:




pravastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-propenoyloxy]phenol ester, corresponding to formula:




- 5 cerivastatin 4-(nitrooxy)butyl ester,  
 cerivastatin 4-(nitrooxymethyl)benzyl ester,  
 cerivastatin 3-(nitrooxymethyl)benzyl ester,  
 cerivastatin 2-(nitrooxymethyl)benzyl ester,  
 cerivastatin 4-(nitrooxymethyl)phenyl ester,  
 10 cerivastatin 3-(nitrooxymethyl)phenyl ester,  
 cerivastatin 2-(nitrooxymethyl)phenyl ester,  
 cerivastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester,  
 corresponding to formula:




cerivastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-propenyloxy]phenol ester, corresponding to formula:



- 5 atorvastatin 4-(nitrooxy)butyl ester,  
 atorvastatin 4-(nitrooxymethyl)benzyl ester,  
 atorvastatin 3-(nitrooxymethyl)benzyl ester,  
 atorvastatin 2-(nitrooxymethyl)benzyl ester,  
 atorvastatin 4-(nitrooxymethyl)phenyl ester,  
 10 atorvastatin 3-(nitrooxymethyl)phenyl ester,  
 atorvastatin 2-(nitrooxymethyl)phenyl ester,  
 atorvastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester,  
 corresponding to formula:



atorvastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-propenoyloxy]phenol ester, corresponding to formula:



rosuvastatin 4-(nitrooxy)butyl ester,

5 rosuvastatin 4-(nitrooxymethyl)benzyl ester,

rosuvastatin 3-(nitrooxymethyl)benzyl ester,

rosuvastatin 2-(nitrooxymethyl)benzyl ester,


rosuvastatin 4-(nitrooxymethyl)phenyl ester,

rosuvastatin 3-(nitrooxymethyl)phenyl ester,

10 rosuvastatin 2-(nitrooxymethyl)phenyl ester,

rosuvastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester,


corresponding to the formula:



15

rosuvastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-propenoyloxy]phenol ester, corresponding to formula:





As mentioned above, object of the present invention are  
5 also pharmaceutical compositions containing at least a  
compound of the present invention of formula (I) together  
with non toxic adjuvants and/or carriers usually employed  
in the pharmaceutical field.

The daily dose of active ingredient that should be  
10 administered can be a single dose or it can be an effective  
amount divided into several smaller doses that are to be  
administered throughout the day. Usually, total daily dose  
may be in amounts preferably from 50 to 500 mg. The dosage  
regimen and administration frequency for treating the  
15 mentioned diseases with the compound of the invention  
and/or with the pharmaceutical compositions of the present  
invention will be selected in accordance with a variety of  
factors, including for example age, body weight, sex and  
medical condition of the patient as well as severity of the  
20 disease, route of administration, pharmacological  
considerations and eventual concomitant therapy with other  
drugs. In some instances, dosage levels below or above the  
aforesaid range and/or more frequent may be adequate, and  
this logically will be within the judgment of the physician  
25 and will depend on the disease state.

The compounds of the invention may be administered  
orally, parenterally, rectally or topically, by inhalation  
or aerosol, in formulations eventually containing

conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term "parenteral" as used herein, includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.

Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions may be formulated according to known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents are water, Ringer's solution and isotonic sodium chloride. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono or diglycerides, in addition fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the active ingredient with a suitable non-irritating excipient, such as cocoa butter and polyethylene glycols.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, granules and gels. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g. lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may

also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavouring and the like.

As previously reported, the new statin nitroderivatives beyond lowering lipid, possess enhanced anti-inflammatory, antiplatelet and antithrombotic effects as compared to native statins. Moreover, they can be effective also in the other pathologies such as acute coronary syndromes, stroke, peripheral vascular diseases such as peripheral ischemia, all disorders associated with endothelial dysfunctions such as vascular complications in diabetic patients and atherosclerosis, neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), autoimmune diseases such as multiple sclerosis.

#### **Study on vascular tone**

The ability of statin nitroderivatives to induce vasorelaxation in comparison to native statins, was tested *in vitro* in isolated rabbit thoracic aorta preparations (Wanstall J.C. et al., Br. J. Pharmacol., 134:463-472, 2001). Male New Zealand rabbits were anaesthetized with thiopental-Na (50 mg/kg, iv), sacrificed by exsanguinations and then the thorax was opened and the aorta dissected. Single ring preparations (4 mm in length) of thoracic aorta were set up in physiological salt solution (PSS) at 37°C in small organ chambers (5 ml). The composition of PSS was (mM): NaCl 130, NaHCO<sub>3</sub> 14.9, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub> 1.2, HEPES 10,

CaCl<sub>2</sub>, ascorbic acid 170 and glucose 1.1 (95% O<sub>2</sub> /5% CO<sub>2</sub>; pH 7.4). Each ring was mounted under 2 g passive tension in 5 ml organ bath. Isometric tension was recorded with a Grass transducer (Grass FT03) attached to a BIOPAC MP150 System. Preparations were allowed to equilibrate for 1 h, then contracted submaximally with noradrenaline (NA, 1 µM) and, when the contraction was stable, acetylcholine (ACh, 10 µM) was added. A relaxant response to ACh indicated the presence of a functional endothelium. When a stable precontraction was reached, a cumulative concentration-response curve to either of the vasorelaxant agents was obtained in the presence of a functional endothelium. Time intervals between different concentrations were based on the time needed to reach a full response. Moreover, the effect of the soluble guanylyl cyclase inhibitor ODQ (1-H-(1,2,4)-oxadiazol(4,3-a)quinoxalin-1-one) on the dilator responses elicited by the compounds was examined preincubating the aortic rings with ODQ (10 µM) for 20 min. Responses to vasorelaxing agents were measured from the plateau of NA contraction. The IC<sub>50</sub> (concentration giving 50% reversal of NA contraction) was interpolated from the plots of relaxant-response vs log molar concentration of tested compound.

During the experimental period, the plateau obtained with NA was stable without significant spontaneous loss of contraction in the aortic rings. Under these experimental conditions, native statins did not produce relaxation up to 30 µM, the curve being not different from that built up in presence of vehicle alone.

As shown in the following Table 1, the nitroderivatives of the invention were able to induce relaxation in a concentration-dependent manner. Furthermore, in experiments

performed in presence of ODQ (10  $\mu$ M), the vasorelaxant responses to all the tested drugs were inhibited.

**TABLE 1**

Compound	IC <sub>50</sub> ( $\mu$ M) $\pm$ sem
Pravastatin	> 30
Compound of <b>EX.1</b>	2.4 $\pm$ 0.6
Fluvastatin	> 30
Compound of <b>EX.3</b>	13.4 $\pm$ 3.5
Compound of <b>EX.4</b>	8.7 $\pm$ 3.3

5

IC<sub>50</sub> is the concentration which inhibits 50% of the response.

10 **Effects of nitrostatin derivatives on inflammatory pathways  
in vitro**

The experiments were performed using RAW264.7 monocyte macrophage cell line. Cells were stimulated in the presence of LPS (1  $\mu$ g/ml) for 8 h (pravastatin and derivative) or 16 h (fluvastatin, atorvastatin and derivatives). At the end of the incubation, the cells were harvested in lysis buffer and the protein content was measured. Western Blot of inducible iNOS and COX2 proteins (representatives of an ongoing inflammatory process) was performed. The obtained results reported in Table 2 are expressed as % reduction of optical density of each treatment vs. LPS-treated samples. Negative results indicate an increase vs. LPS alone.

TABLE 2

Compound	Concentration ( $\mu$ M)	iNOS (% reduction vs LPS)	COX2 (% reduction vs LPS)
Fluvastatin	10	-14.8 $\pm$ 5.9	-2.8 $\pm$ 3.7
Compound of EX.3	10	44.8 $\pm$ 11.9	53.9 $\pm$ 6.1
Compound of EX.4	10	22.4 $\pm$ 9.6	19.4 $\pm$ 6.5
Pravastatin	100	4.7 $\pm$ 3.6	26.9 $\pm$ 7.9
Compound of EX.1	100	55.2 $\pm$ 11.8	74.9 $\pm$ 4.4
Atorvastatin	10	20 $\pm$ 14	-
Compound of EX.7	10	45 $\pm$ 9	-

Nitroderivatives of fluvastatin, pravastatin and  
 5 atorvastatin exert, in RAW264.7 cell line, a significant  
 inhibitory action on the expression of proteins, such as  
 COX2 and iNOS, that are recognised to be relevant in the  
 inflammatory process. Conversely, these effects are not  
 detectable or weak for the parent compounds.

10

#### Study of the activity of pravastatin nitroderivative on peripheral vascular disease

Angiogenesis is a primary response to local tissue  
 15 hypoxia and is likely involved in the restoration of  
 blood flow in ischemic diseases such as acute coronary  
 syndromes and occlusive peripheral vascular disease.

The ability of pravastatin nitroderivative (compound of  
 EX.1) to inhibit the angiogenic process was evaluated  
 20 using an *in vivo* model of murine hindlimb ischemia as  
 previously described (Emanuelli et al., Circulation 103,125-  
 132, 2001). Briefly, 2 month-old CD1 male mice (Charles

River, Italy) mice were randomly allocated into 3 groups (n=20 each) feed rat chow containing: 1) pravastatin (40 mg/kg), 2) pravastatin nitroderivative (48 mg/kg), 3) vehicle (regular chow). After 3 days, mice were anaesthetized and left hindlimb ischemia was induced by electro-coagulation of the upper part of femoral artery. Treatment was continued for the following 2 weeks after surgery. Systolic blood pressure was measured by tail cuff technique at 7 and 14 days. The clinical outcome at 14 days was determined by counting the number of necrotic or lost nails in the ischemic foot as well as the number of auto-amputation events. At 14 days from ischemia induction, hindlimbs of anaesthetized mice were perfusion-fixed, both adductors were coded and histologically processed. Capillary and arteriolar densities ( $n_{cap}/mm^2$  and  $n_{art}/mm^2$ ) were determined.

TABLE 3

Compound	N capillaries /mm <sup>2</sup> in ischemic adductor muscle	N capillaries /mm <sup>2</sup> in contralateral adductor muscle
Vehicle	852±32 <sup>ss</sup>	685±38
Pravastatin	823±42	736±40
Compound of EX.1	1116±53 <sup>ss***</sup>	660±40

\*\* P<0.01 vs. vehicle ; \*\* P<0.01 vs. pravastatin; <sup>ss</sup> P<0.01 vs. respective contralateral group

As shown in Table 3, differently from the parent compound, the compound of the invention was able to potentiate the native reparative capillarization response to ischemia. The results of the present study indicate that the nitroderivative promotes a significant reparative neovascularization and ameliorates clinical outcome in mice with experimentally-induced hindlimb ischemia.

**Effect of pravastatin nitroderivative on leukocytes adhesion in ApoE knockout mice**

5        The interaction between leukocytes and the vascular endothelium is a crucial inflammatory step in the atherogenic process. The ability of pravastatin nitroderivative (compound of EX.1) to inhibit leukocyte adhesion was investigated ex vivo in atherosclerotic (ApoE  
10        knockout) mice.

      Three groups of ApoE knockout mice were dosed with pravastatin (40mg/kg po), pravastatin nitroderivative (equimolar dose) or vehicle daily for 5 days and euthanised by CO<sub>2</sub> euthanised by CO<sub>2</sub> asphyxiation 1h after the last  
15        dose.

      Leukocytes were isolated from spleen, centrifuged, RBCs lysed with water. Arterial segments prepared - aortic & thoracic regions opened longitudinally and pinned out luminal side up. Radiolabelled  
20        leukocytes (<sup>51</sup>Cr-leukocytes) are incubated with thrombin-stimulated (10U/mL-1 for 10 min.) segments for 30 min. Segments are washed with medium and adhesion measured by gamma counter.

25

**TABLE 4**

Compound	ApoE K/O mice
	Leukocyte adhesion (%) (thoracic aorta)
Vehicle	23.4 ± 5
Pravastatin	23.0 ± 6
Compound of EX.1	9.3 ± 3 * #

\* P< 0.05 vs vehicle ; # P< 0.05 vs pravastatin



As shown in Table 4, differently from the parent compound, the compound of the invention was able to reduce the thrombin-induced adhesive interaction between isolated leukocytes and the blood vessel wall in both strains of mice.

These data demonstrate that the nitroderivative exerts anti-atherogenic/anti-inflammatory effects.

#### Study of antithrombotic activity of pravastatin nitroderivative in vivo

The ability of pravastatin nitroderivative to inhibit thrombus formation was evaluated in male Charles Rivers CD-1 mice (20-25 g) given pravastatin (10 or 20 mg/kg ip), compound of EX.1 (equimolar doses) or vehicle. 1-3 hrs later the animals were injected into a tail vein with U46619 (0.2 mg/kg), a stable TxA<sub>2</sub> analog. As previously described (Momi et al., Eur. J. Pharmacol. 397:177-185, 2000), this dose of the agonist caused 80 to 90% mortality within 3 min. in the control group. In each experimental session at least six animals per treatment group were tested; control groups were run at the beginning and at the end of every experimental session. Protection against agonist-induced thromboembolism was expressed as  $(1 - T_{\text{drug}}/T_{\text{saline}}) \times 100$ , where  $T_{\text{drug}}$  is the mortality rate in drug-treated mice, and  $T_{\text{saline}}$  is the number of non surviving control animals which received thrombin only.

The results were expressed as percentage of protection from U46619-induced pulmonary thromboembolism as compared to the control group.

TABLE 5

Compound	Antithrombotic activity (%) 1-h before challenge	Antithrombotic activity (%) 3-h before challenge
Vehicle	0	0
Pravastatin 10 mg/kg ip	15	10
20 mg/kg ip	25	20
Compound of EX.1 12 mg/kg ip	30*	40*
24 mg/kg ip	40* +	55* +

5 \*P< 0.05 vs control ; + P< 0.05 vs pravastatin

As shown in Table 5, differently from the parent compound, the compound of the invention was able to inhibit thrombosis induced by U46619.

10

#### Study of antiplatelet activity of pravastatin nitroderivative in vitro

Platelets are prominent components of the thrombi. The ability of pravastatin nitroderivative (compound of EX.1) to inhibit platelet aggregation was evaluated in vitro in human platelets. Platelet aggregation was measured in 0.25 ml platelet rich plasma (PRP) or gel filtered platelets (GFP) samples as previously described (Vezza R, et al., Blood 73: 2006-2013, 1993).

20

Compounds were incubated at 37°C for 2 min before adding U46619, an aggregating agent, TxA<sub>2</sub> analog. Aggregation was followed for 5 min and the maximal amplitude (cm) was measured. DMSO (0.05% ) was used as vehicle. Compounds were tested at concentrations ranging from 50 to 200µM.

25

TABLE 6

Compound	Platelet aggregation (GFP)	Platelet aggregation (PRP)
	IC <sub>50</sub> $\mu$ M	IC <sub>50</sub> $\mu$ M
Pravastatin	> 200	> 200
Compound of EX.1	101 $\pm$ 10	74 $\pm$ 7

As shown in Table 6, differently from the parent compound, the nitroderivative of the invention was able to inhibit platelet aggregation induced by U46619.

**Effect of pravastatin nitroderivative on inhibition of Tissue Factor expression in vitro**

Tissue factor (TF) is a major regulator of homeostasis and thrombosis. The ability of pravastatin nitroderivative (compound of EX.1) to inhibit TF expression was evaluated in isolated human blood mononuclear cell (MNC) preparations. MNC were obtained from fresh blood by density gradient (Ficoll-Hypaque) centrifugation and resuspended in serum-free RPMI medium at the concentration of  $2-3 \times 10^6$ /ml. Pravastatin nitroderivative (3-50  $\mu$ M) or pravastatin (50  $\mu$ M) was added to cell suspensions prior to exposure to LPS (1  $\mu$ g/ml). After incubation for 3 h at 37°C, TF expression in MNC was assessed by 1) functional assay (Semeraro et al., 1983. Immunology; 50: 529-35 ) on intact cells; 2) immunological assay (Imubind, Instrumentation Laboratory, Milan) on Triton X-100 cell extracts; 3) RT-PCR (Rossiello et al. Thromb Haemost 2000; 84:453-59).

TABLE 7

Compound	TF in LPS-stimulated MNC	
	Activity (AU/10 <sup>6</sup> cells) <sup>s</sup>	Antigen (ng/mg protein)
Vehicle (DMSO 0.1%)	178 ± 36.2	5.0 ± 1.1
Pravastatin (50 µM)	189 ± 37.6	4.4 ± 1.3
Compound of EX.1 (50 µM)	16 ± 4.9 **	0.65 ± 0.11**

Data are the mean ± SEM of 4-5 experiments.

<sup>s</sup>Arbitrary units calculated by reference to a standard curve constructed with human relipidated tissue factor

5 \*\* P < 0.01 vs pravastatin and vehicle

As shown in Table 7, differently from the parent compound, the compound of the invention markedly inhibited LPS-induced TF expression (activity and antigen).


10 The results of the present study indicate that the nitroderivative exerts antithrombotic activity.

The following examples are to further illustrate the invention without limiting it.

15

#### General procedure

The compound of general formula (I), wherein X = O, can be obtained by reacting a compound of formula (II)



20

(II)

wherein M is hydrogen or an alkali metal or alkaline earth metal, such as sodium or calcium, with a compound of formula (III)

A-Y-B (III)

25 wherein A is a leaving group such as chlorine, bromine, iodine, a tosyl or mesyl group, B is selected from chlorine, bromine, iodine or a nitrooxy group and Y is as

defined above in formula (I), in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, benzene, toluene, at a temperature ranging from room temperature to 50°C. The reaction is terminated within 30 min to 24 h.

5       The compounds of formula (II) are known compounds  
available on the market or can be prepared according to  
methods well known in the literature. The compounds of  
formula (III), wherein A is as above defined and B is Cl,  
Br, I, are commercially available or can be synthesized  
10 according to methods well known in the literature.

The compounds of formula (III), wherein A is as above defined and B is  $\text{ONO}_2$ , are synthesized by conversion of a compound of formula (III) wherein B is Cl, Br, I into the corresponding nitro derivative by reaction with a nitrate source such as silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl is  $\text{C}_1\text{-C}_{10}$  alkyl) in a suitable organic solvent such as acetonitrile, tetrahydrofuran, methyl ethyl ketone, ethyl acetate, DMF, the reaction is carried out, in the dark, at a temperature from room temperature to the boiling temperature of the solvent. The reaction is terminated within 30 min to 3 days. Preferred nitrate source is silver nitrate.

25        The compound of formula (I), in which X = O, S, NH or NR<sup>1</sup>, R<sup>1</sup> being as above defined, can be obtained by reacting a compound of formula (II) wherein M is hydrogen, in presence of a dehydrating agent, with a compound of formula (IV)

30 D-Y-B (IV)

wherein Y e B are as defined above and D is selected from NH<sub>2</sub>, NHR<sup>1</sup>, OH or SH, R<sup>1</sup> being as above defined. Preferred dehydrating agents are N,N'-carbonyldiimidazole, used in

presence of a catalytic amount of sodium ethylate, DCC  
EDAC. The reaction is performed in an inert organic solvent  
such as N.N'-dimethylformamide, tetrahydrofurane, benzene,  
toluene, a polyhalogenated aliphatic hydrocarbon, at a  
5 temperature ranging from -50°C to 50°C for between 30 min  
and 24 h.

The compounds of formula (IV), wherein D is as above  
defined and B is Cl, Br, I, are commercially available or  
synthesized according to methods well known in the  
10 literature.


For example they can be obtained from the corresponding  
hydroxy derivative of formula (V) D-Y-OH, by reaction with  
thionyl or oxalyl chloride, halides of P<sup>III</sup> or P<sup>V</sup>, mesyl  
chloride, tosyl chloride in solvents inert such as toluene,  
15 chloroform, DMF, etc.

The compounds of formula (IV), wherein D is as above  
defined and B is ONO<sub>2</sub>, can be obtained by reaction of the  
compounds of formula (IV) wherein B is Cl, Br, I, with a  
nitrate source as above described. Alternatively the  
20 compounds of formula (IV) wherein B is ONO<sub>2</sub>, can be  
obtained by the corresponding hydroxy compounds of formula  
(V) by reaction with nitric acid and acetic anhydride in a  
temperature range from -50°C to 0°C according to methods  
well known in the literature.

25

#### Example 1

Synthesis of [1S-[1p(pS\*,pS\*),2p,6p,8p-(R\*),8ap]]-  
1,2,6,7,8,8a-hexahydro-p,p,6-trihydroxy-2-methyl-8-(2-  
30 methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid 4-  
(nitrooxy)butyl ester (pravastatin 4-(nitrooxy)butyl  
ester)



a) [1S-[1p(μS\*, μS\*), 2p, 6p, 8p-(R\*), 8ap]]-1,2,6,7,8,8a-Hexahydro-μ,μ,6-trihydroxy-2-methyl-8-(2-methyl-1-

5 oxobutoxy)-1-naphthaleneheptanoic acid 4-bromobutyl ester

To a solution of pravastatin sodium (9.25 g, 21 mmol) in N,N-dimethylformamide (70 ml) a mixture of 1,4-dibromobutane (3.68 ml, 31 mmol) in N,N-dimethylformamide (30 ml) was added dropwise. The reaction mixture was  
 10 stirred at room temperature for 24 h. The solution was then treated with water and diethyl ether, the organic layers were dried with sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography, with n-hexane/ethyl acetate 3/7 as eluent.  
 15 The title compound was obtained as a white powder (7.8 g).

b) [1S-[1p(μS\*, μS\*), 2p, 6p, 8p-(R\*), 8ap]]-1,2,6,7,8,8a-Hexahydro-μ,μ,6-trihydroxy-2-methyl-8-(2-methyl-1-

20 oxobutoxy)-1-naphthaleneheptanoic acid 4-(nitrooxy)-butyl ester

A solution of the compound obtained as described in a) above (7.7g, 14 mmol) and silver nitrate (3.5g, 21 mmol) in acetonitrile (90 ml) was stirred at 40°C, in the dark, for 48 h. The precipitate thus formed (silver salt) was  
 25 filtered off and the solvent was evaporated under vacuum. The residue was then purified by flash chromatography, with n-hexane/ethyl acetate 3/7 as eluent. The title compound was obtained as a white powder (3.7 g) melting at 63°C.


<sup>1</sup>H-NMR:  $\mu$  (CDCl<sub>3</sub>) 6.00 (1H, m); 5.88 (1H, m); 5.53 (1H, s); 5.40 (1H, s); 4.51 (2H, t); 4.40 (1H, m); 4.26 (1H, m); 4.15 (2H, t); 3.78 (1H, m); 2.60-2.23 (6H, m); 1.8-1.20 (14H, m); 1.10 (3H, d); 0.87 (6H, t).

5

**Example 2**

Synthesis of [1S-[1 $\mu$ ( $\mu$ S\*,  $\mu$ S\*), 2 $\mu$ , 6 $\mu$ , 8 $\mu$ - (R\*), 8a $\mu$ ]]-1,2,6,7,8,8a-hexahydro- $\mu$ , $\mu$ ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid 4-(nitrooxymethyl)benzyl ester (pravastatin 4-(nitrooxymethyl)benzyl ester)

10



15 a) 1S-[1 $\mu$ ( $\mu$ S\*,  $\mu$ S\*), 2 $\mu$ , 6 $\mu$ , 8 $\mu$ - (R\*), 8a $\mu$ ]]-1,2,6,7,8,8a-Hexahydro- $\mu$ , $\mu$ ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid 4-(chloro-methyl)benzyl ester

To a solution of  $\mu$ , $\mu$ '-dichloro-p-xylene (5.5 g, 31 mmol) in N,N-dimethylformamide (70 ml) pravastatin sodium (7 g, 15 mmol) was added portionwise. The reaction mixture was stirred at room temperature for 24 h. The solution thus obtained was then treated with water and ethyl acetate, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography, with n-hexane/ethyl

25



acetate 1/1 as eluent. The title compound was obtained as a white powder (5.5 g) and was employed as such in the following step without further purification.


- 5    b)            [1S-[1p(pS\*,pS\*),2p,6p,8p-(R\*),8ap]]-1,2,6,7,8,8a-Hexahydro-p,p,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid 4-(nitrooxymethyl)benzyl ester

A solution of the compound obtained as described in a) above (5.5 g, 7.7 mmol) and silver nitrate (2.5 g, 15 mmol) in acetonitrile (60 ml) was stirred at 60°C, in the dark, for 48 h. The precipitate thus formed (silver salt) was filtered off and the solvent was evaporated under vacuum. The residue was then purified by flash chromatography, with  
15    n-hexane/ethyl acetate 1/1 as eluent. The title compound (1.6 g) was obtained as white powder melting at 80-82°C.

<sup>1</sup>H-NMR    p(CDCl<sub>3</sub>): 7.39 (4H,m);    5.98 (1H,m);    5.86 (1H,m);  
5.54 (1H,s); 5.42 (3H,s); 5.16 (2H,s); 4.40 (1H,m); 4.27 (1H,m);  
3.80 (1H,m); 2.52 (3H,m); 2.45-2.25 (3H,m); 1.74-1.10 (10H,m);  
20    1.10 (3H,d); 0.87 (6H,t).

### Example 3

- Synthesis of [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid  
25    4-(nitrooxy)butyl ester (fluvastatin 4-(nitrooxy)butyl ester)



a) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 4-bromobutyl ester

5 To a solution of 1,4-dibromobutane (4.1 ml, 34 mmol) in N,N-dimethylformamide (60 ml) a mixture of fluvastatin sodium (5 g, 11 mmol) in N,N-dimethylformamide (40 ml) was added dropwise. The reaction mixture was stirred at room temperature for 24 h. The resulting solution was then  
10 treated with water and diethyl ether, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography, with n-hexane/iso-propanol 8.5/1.5 as eluent. The title compound was obtained as yellow oil (4.7  
15 g) and was employed in the following step without further purification.


b) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 4-(nitrooxy)butyl ester

20 A solution of the compound obtained as described in a) above (4.7 g, 8.5 mmol) and silver nitrate (2.9 g, 17 mmol) in acetonitrile (60 ml) was stirred at 60°C, in the dark, for 48 h. The precipitate thus formed (silver salt) was  
25 filtered off and the solvent was evaporated under vacuum. The residue was then purified by flash chromatography, with n-hexane/ethyl acetate 1/1 as eluent. The desired product (0.5 g) was obtained as white powder melting at 112°C.

<sup>1</sup>H-NMR  $\mu$ (DMSO): 7.69(1H,d); 7.43(3H,m); 7.27(2H,t);  
30 7.25(1H,t); 7.03(1H,t); 6.65(1H,d); 5.75(1H,dd);  
4.98(1H,d); 4.90(1H,m); 4.78(1H,d); 4.50(2H,t); 4.25(1H,m);  
4.09(2H,t); 3.9(1H,m); 2.4(2H,m); 1.67(4H,m); 1.61(6H,d);  
1.42(2H,m).

**Example 4**

Synthesis of [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 4-(nitrooxymethyl)benzyl ester (fluvastatin 4-  
 5 (nitrooxymethyl)benzyl ester)



a) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-  
indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 4-  
 10 (chloromethyl)benzyl ester

To a solution of  $\mu,\mu'$ -dichloro-p-xylene (10 g, 57 mmol) in N,N-dimethylformamide (60 ml) a mixture of fluvastatin sodium (10 g, 23 mmol) in N,N-dimethylformamide (80 ml) was added dropwise. The reaction mixture was stirred in the  
 15 dark at room temperature for 12 h. The solution was then treated with water and ethyl acetate, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography, with n-hexane/ethyl acetate 1/1 as eluent.  
 20 The title compound (9.4 g) was obtained as white powder by crystallization from n-hexane.

b) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-  
indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 4-  
 25 (nitrooxymethyl)benzyl ester


A solution of the compound described in a) above (9.4 g, 17 mmol) and silver nitrate (10.6 g, 63 mmol) in

acetonitrile (180 ml) was stirred at 50°C, in the dark, for 24 h. The precipitate thus obtained (silver salt) was filtered off and the solvent was evaporated under vacuum. The residue was then purified by flash chromatography, with  
 5 n-hexane/ethyl acetate 4/6 as eluent to give the desired product (4 g) as a white powder melting at 103-104°C.

<sup>1</sup>H-NMR  $\mu$ (DMSO): 7.65(1H,d); 7.42(7H,m); 7.22(2H,t); 7.15(1H,t); 7.03(1H,t); 6.64(1H,d); 5.75(1H,dd); 5.51(2H,s); 5.12(2H,s); 4.98(1H,d); 4.88(1H,t); 4.84(1H,d);  
 10 4.27(1H,t); 3.94(1H,t); 2.4-2.6(2H,m); 1.4-1.7(2H,M); 1.57(6H,d).

#### Example 5

Synthesis of [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid  
 15 3-(nitrooxymethyl)benzyl ester (fluvastatin 3-(nitrooxymethyl)benzyl ester)



20 a) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid  
3-(chloromethyl)benzyl ester

To a solution of  $\mu,\mu'$ -dichloro-m-xylene (0.95 g, 5.4 mmol) in N,N-dimethylformamide (25 ml) a mixture of  
 25 fluvastatin sodium (0.79 g, 1.8 mmol) in N,N-dimethylformamide (25 ml) was added dropwise. The reaction

mixture was stirred in the dark at room temperature for 24 h. The solution thus formed was then treated with water and ethyl acetate, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The  
 5 residue was purified by silica gel chromatography, with n-hexane/ethyl acetate 1/1 as eluent, to give 0.41 g of the title compound.


b) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 3-(nitrooxymethyl)benzyl ester

A solution of the compound described above (0.4 g, 0.7 mmol) and silver nitrate (0.36 g, 2.1 mmol) in acetonitrile (30 ml) was stirred at 45°C, in the dark, for 24 h. The  
 15 precipitate thus obtained (silver salt) was filtered off and the solvent was evaporated under vacuum. The residue was purified by flash chromatography, with methylene chloride/iso-propanol 9.5/0.5 as eluent to give the desired product (0.2 g).

20 <sup>1</sup>H-NMR:  $\mu$ (DMSO): 7.67(1H,d); 7.47-7.40(7H,m); 7.25-7.10(3H,m); 7.05(1H,t); 6.62(1H,d); 5.72(1H,dd); 5.49(2H,s); 5.13(2H,s); 5.00-4.84(3H,m); 4.27(1H,m); 3.95(1H,m); 2.60-2.35(2H,m); 1.58(6H,d); 1.70-1.45(2H,m).

## 25 Example 6

Synthesis of [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 2-(nitrooxymethyl)benzyl ester (fluvastatin 2-(nitrooxymethyl)benzyl ester)



a) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 2-  
 5 (chloromethyl)benzyl ester

To a solution of *p,p'*-dichloro-*o*-xylene (1.5 g, 3.4 mmol) in *N,N*-dimethylformamide (15 ml) a mixture of fluvastatin sodium (1.5 g, 8.6 mmol) in *N,N*-dimethylformamide (15 ml) was added dropwise. The reaction  
 10 mixture was stirred in the dark at room temperature for 24 h. The solution thus obtained was treated with water and ethyl acetate, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography, with *n*-  
 15 hexane/ethyl acetate 6/4 as eluent to give 0.97 g of the title compound.

b) [R\*,S\*-(E)]-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptanoic acid 2-  
 20 (nitrooxymethyl)benzyl ester

A solution of the compound obtained as described above (0.97 g, 1.7 mmol) and silver nitrate (1.3 g, 7.6 mmol) in acetonitrile (40 ml) was stirred at 40°C, in the dark, for 24 h. The precipitate thus formed (silver salt) was  
 25 filtered off and the solvent was evaporated under vacuum. The residue was then purified by flash chromatography, with


n-hexane/iso-propanol 8.5/1.5 as eluent to give the desired product (0.42 g) as yellow powder.

<sup>1</sup>H-NMR  $\mu$ (DMSO): 6.52 (1H,m); 7.47-7.30 (7H,m); 7.24-7.14 (3H,m); 7.03 (1H,t); 6.27 (1H,d); 5.70 (1H,dd);  
 5 5.66 (2H,s); 5.22 (2H,s); 4.98 (1H,m); 4.84 (1H,t); 4.82 (1H,d);  
 4.30 (1H,m); 3.90 (1H,m); 2.40 (2H,m); 1.58 (6H,d); 1.40 (2H,m).

10

### Example 7

Synthesis of ( $\mu$ R, $\mu$ R)-2(4-fluorophenyl)- $\mu,\mu$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbon-yl]-1H-pyrrole-1-heptanoic acid 4-(nitrooxy)butyl ester  
 15 (atorvastatin 4-(nitrooxy)butyl ester)



a) ( $\mu$ R, $\mu$ R)-2(4-fluorophenyl)- $\mu,\mu$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid 4-bromobutyl ester

20 To a solution of 1,4-dibromobutane (0.34 ml, 2.88 mmol) in N,N-dimethylformamide (10 ml) a mixture of atorvastatin calcium (0.83 g, 0.72 mmol) in N,N-dimethylformamide (10 ml) was added dropwise. The reaction mixture was stirred at room temperature for 24 h. The solution was then treated  
 25 with water and diethyl ether, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel

chromatography, with n-hexane/ethyl acetate 6/4 as eluent to give the title compound (0.26 g) as a white solid.

b) (pR, pR)-2(4-fluorophenyl)-p,p-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid 4-(nitrooxy)butyl ester

A solution of the compound obtained in a) above (0.25 g, 0.36 mmol) and silver nitrate (0.38 g, 2.2 mmol) in acetonitrile (10 ml) was stirred at 50°C, in the dark, for 21 h. The precipitate thus formed (silver salt) was filtered off and the solvent was evaporated under vacuum. The residue was then purified by silica gel chromatography, with n-hexane/ethyl acetate 1/1 as eluent to give the desired product (0.21g) as white powder.


<sup>1</sup>H-NMR  $\mu$ (DMSO): 9.80 (1H, s); 7.51 (2H, d); 7.26-7.19 (6H, m); 7.09-6.95 (6H, m); 4.73 (1H, d); 4.61 (1H, d); 4.54 (2H, t); 4.04 (2H, t); 4.00-3.70 (3H, m); 3.50 (1H, m); 3.22 (1H, m); 2.40 (1H, dd); 2.25 (1H, dd); 1.80-1.10 (8H, m); 1.38 (6H, d).

According to Examples 1-7 further compounds of the invention can be obtained starting from appropriate reactants and employing also cerivastatin and rosuvastatin instead of pravastatin, fluvastatin and atorvastatin.



## CLAIMS



1. A compound of general formula (I) or a pharmaceutically  
5 acceptable salt or stereoisomer thereof





(I)


wherein:

- X is -O-, -S-, -NH- or -NHR<sup>1</sup>-, R<sup>1</sup> being straight or  
10 branched alkyl with 1 to 10 carbon atoms, preferably CH<sub>3</sub>;  
R is a statin residue of formula





or



5


Y is a bivalent radical having the following meaning:

a)


- straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene, preferably C<sub>1</sub>-C<sub>10</sub>,  
 10 being optionally substituted with one or more of the  
 substituents selected from the group consisting of:  
 halogen atoms, hydroxy, -ONO<sub>2</sub> or T<sub>0</sub>, wherein T<sub>0</sub> is -  
 OC(O)(C<sub>1</sub>-C<sub>10</sub> alkyl)-ONO<sub>2</sub> or -O(C<sub>1</sub>-C<sub>10</sub> alkyl)-ONO<sub>2</sub>;

- cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being eventually substituted with side chains T, wherein T is straight or branched alkyl with from 1 to 10 carbon atoms, preferably CH<sub>3</sub>;

b)




c)



- 10 wherein  $n$  is an integer from 0 to 20, and  $n^1$  is an integer from 1 to 20;


d)



wherein:

- 15  $n^1$  is as defined above and  $n^2$  is an integer from 0 to 2;  
 $X_1 = -OCO-$  or  $-COO-$  and  $R^2$  is H or  $CH_3$ ;


e)



wherein:

- 20  $n^1$ ,  $n^2$ ,  $R^2$  and  $X_1$  are as defined above;  
 $Y^1$  is  $-CH_2-CH_2-$  or  $-CH=CH-(CH_2)_{n^2}-$ ;

f)




wherein:

$n^1$  and  $R^2$  are as defined above,  $R^3$  is H or  $\text{COCH}_3$ ;

- 5 with the proviso that when Y is selected from bivalent radicals mentioned under b)-f), the  $-\text{ONO}_2$  group is bound to  $-(\text{CH}_2)_{n^1}$ ;


g)



10

wherein  $\text{X}_2$  is  $-\text{O}-$  or  $-\text{S}-$ ,  $n^3$  is an integer from 1 to 6, preferably from 1 to 4,  $R^2$  is as defined above;

h)



- 15 wherein:


$n^4$  is an integer from 0 to 10;

$n^5$  is an integer from 1 to 10;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  are the same or different, and are H or straight or branched  $\text{C}_1$ - $\text{C}_4$ -alkyl, preferably  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$

- 20 are H;


wherein the  $-\text{ONO}_2$  group is bound to



$n^5$  being as defined above;

$Y^2$  is a 5 or 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and selected for

5 example from



10

2. A compound of general formula (I) and/or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 1 wherein:

X is -O- or -S-;


R is a statin residue as defined in claim 1;

Y is a bivalent radical having the following meaning:


a)

20 - straight or branched  $C_1$ - $C_{10}$  alkylene, being optionally substituted with  $T_0$ , wherein  $T_0$  is as defined in claim 1;

b)




c)



5 wherein  $n$  is an integer from 0 to 5, and  $n^1$  is an integer from 1 to 5;

d)




10 wherein:

$n^1$  is as defined above and  $n^2$  is an integer from 0 to 2;

$X_1 = -OCO-$  or  $-COO-$  and  $R^2$  is H or  $CH_3$ ;

e)




15 wherein:

$n^1$ ,  $n^2$ ,  $R^2$  and  $X_1$  are as defined above;

$Y^1$  is  $-CH=CH-$ ;

f)




20 wherein:

$n^1$  and  $R^2$  are as defined above,  $R^3$  is H or  $COCH_3$ ;

with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the  $-\text{ONO}_2$  group is bound to  $-(\text{CH}_2)_n^1$ ;

g)



wherein  $\text{X}_2$  is  $-\text{O}-$  or  $-\text{S}-$ ,  $n^3$  is an integer from 1 to 4, preferably 1,  $\text{R}^2$  is as defined above;

h)




wherein:

$n^4$  is an integer from 0 to 3;


$n^5$  is an integer from 1 to 3;

$\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$  are the same and are H;

and wherein the  $-\text{ONO}_2$  group is linked to



$\text{Y}^2$  is a 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or more atoms of nitrogen and selected for example from



3. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 4-(nitrooxy)butyl ester.

5

4. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 4-(nitrooxymethyl)-benzyl ester.

10 5. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 3-(nitrooxymethyl)-benzyl ester.

15 6. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 2-(nitrooxymethyl)-benzyl ester.

20 7. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 4-(nitrooxymethyl)-phenyl ester.

25 8. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 3-(nitrooxymethyl)-phenyl ester.

9. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 2-(nitrooxymethyl)-phenyl ester.

30 10. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 2-[2'-(nitrooxy)ethyloxy]ethyl ester.



11. A compound of formula (I) according to claim 1, that is pravastatin, fluvastatin, cerivastatin, rosuvastatin and atorvastatin 2-methoxy-4-[[4'-(nitrooxy)butyl]trans-2-propenoyloxy]phenol ester.

5

12. A compound of formula (I) according to claims 1-11 for use as a medicament.

13. Use of a compound according to claims 1-11 for  
10 preparing a drug having anti-inflammatory, antithrombotic and antiplatelet activity.

14. Use of a compound according to claims 1-11 for  
preparing a drug for reducing cholesterol and triglycerides  
15 levels and/or for raising HDL-C levels.

15. Use of a compound according to claims 1-11 for  
preparing a drug that can be employed for treating acute  
coronary syndromes, stroke, peripheral vascular diseases  
20 and all disorders associated with endothelial dysfunctions.

16. Use of a compound according to claim 15 for treating  
peripheral ischemia, vascular complications in diabetic  
patients and atherosclerosis.

25

17. Use of a compound according to claims 1-11 for  
preparing a drug that can be employed for treating  
neurodegenerative and autoimmune disorders.

30 18. Use of a compound according to claim 17 for treating  
Alzheimer's disease, Parkinson's disease and multiple  
sclerosis.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof according to claims  
5 1-11.

20. A pharmaceutical composition according to claim 19 in a suitable form for the oral, parenteral, rectal, topic and transdermic administration, by inhalation spray or aerosol  
10 or iontophoresis devices.

21. Liquid or solid pharmaceutical composition for oral, parenteral, rectal, topic and transdermic administration or inhalation in form of tablets, capsules and pills  
15 eventually with enteric coating, powders, granules, gels, emulsions, solutions, suspensions, syrups, elixir, injectable forms, suppositories, in transdermal patches or liposomes, containing a compound of formula (I) according to claim 1-11 and/or a salt or stereoisomer thereof and a  
20 pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound of formula (I), at least a compound used to treat cardiovascular disease and a pharmaceutically acceptable  
25 carrier.

23. A pharmaceutical composition according to claim 22, wherein the compound used to treat cardiovascular disease is selected from the group consisting of: ACE inhibitors,  
30 angiotensin II receptor antagonists, beta-adrenergic blockers, calcium channel blockers, antithrombotics, aspirin, nitrosated ACE inhibitors, nitrosated angiotensin

II receptor antagonists, nitrosated beta-adrenergic blockers and nitrosated aspirin.

24. A pharmaceutical kit comprising the composition of  
5 claim 19 and a compound used to treat cardiovascular disease.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP2004/050897

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/405 A61K31/40 C07D209/26 C07D207/34 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/16405 A (NICOX SA (IT)) 9 May 1997 (1997-05-09) the whole document	1-24
A	WO 03/007846 A (WEISS (US)) 30 January 2003 (2003-01-30) the whole document	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*8\* document member of the same patent family

Date of the actual completion of the international search

8 September 2004

Date of mailing of the international search report

21/09/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cortés, J

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/050897

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9716405	A	09-05-1997	IT MI952263 A1	30-04-1997
			AT 193883 T	15-06-2000
			AU 709338 B2	26-08-1999
			AU 7495096 A	22-05-1997
			BR 9611175 A	30-03-1999
			CA 2235996 A1	09-05-1997
			DE 69608916 D1	20-07-2000
			DE 69608916 T2	11-01-2001
			WO 9716405 A1	09-05-1997
			EP 0871606 A1	21-10-1998
			ES 2148808 T3	16-10-2000
			GR 3033827 T3	31-10-2000
			HU 9802986 A2	28-04-1999
			JP 11514636 T	14-12-1999
			PT 871606 T	30-11-2000
			RU 2165921 C2	27-04-2001
			SI 871606 T1	31-08-2000
			US 6040341 A	21-03-2000
WO 03007846	A	30-01-2003	US 2003100493 A1	29-05-2003
			WO 03007846 A1	30-01-2003